$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
【用药须知】卡非佐米是什么药?怎么使用效果好?
2025-10-19 11:44:20
Check Details
【重磅】FDA批准卡非佐米(Kyprolis)用于多发性骨髓瘤的治疗
2025-10-19 11:44:20
Check Details
普乐沙福多少钱一盒?在哪里买便宜?看完就知道了
2025-10-19 11:44:20
Check Details
【医保资讯】2021年普乐沙福在国内进入国家医保了吗?
2025-10-19 11:44:20
Check Details
【关注度高】普乐沙福属于国家医保报销药品吗?
2025-10-19 11:44:20
Check Details
【你所关注】普乐沙福(释倍灵)对多发性骨髓瘤的疗效和安全性
2025-10-19 11:44:20
Check Details
患者使用普乐沙福治疗多发性骨髓瘤的禁忌和注意事项
2025-10-19 11:44:20
Check Details
普乐沙福注射液(释倍灵)在国内纳入国家医保了吗?
2025-10-19 11:44:20
Check Details
普乐沙福注射液(释倍灵)在国内被批准用于治疗多发性骨髓瘤
2025-10-19 11:44:20
Check Details
【患者关心】普乐沙福是根据体重确定用量吗?
2025-10-19 11:44:20
Check Details
【患者关心】伊沙佐米用于多发性骨髓瘤的疗效和安全性
2025-10-19 11:44:20
Check Details
【用药早知道】伊沙佐米是化疗药物还是靶向药物?
2025-10-19 11:44:20
Check Details
1
2
...
1138
1139
1140
1141
1142
1143
1144
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
2
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
3
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
4
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
8
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
9
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
10
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
11
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
12
Chemical Structure of Capivasertib: A Novel AKT Inhibitor